Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain. The company also develops Solriamfetol (JZP-110), which is in phase III clinical trial for the treatment of excessive sleepiness (ES) in patients with narcolepsy and obstructive sleep apnea, as well as in phase II clinical trial for ES associated with Parkinson's disease; Vyxeos for high-risk acute myeloid leukemia; and JZP-507 and JZP-258 to treat EDS and cataplexy in narcolepsy. In addition, it evaluates deuterated oxybate for narcolepsy; and sells psychiatry and other products. The company is headquartered in Dublin, Ireland.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:JAZZ
CUSIPG5087110
Phone353-1634-7800
Debt
Debt-to-Equity Ratio0.54
Current Ratio3.76
Quick Ratio3.62
Price-To-Earnings
Trailing P/E Ratio16.32
Forward P/E Ratio13.32
P/E Growth0.85
Sales & Book Value
Annual Sales$1.62 billion
Price / Sales5.82
Cash Flow$13.0209 per share
Price / Cash11.98
Book Value$45.26 per share
Price / Book3.45
Profitability
EPS (Most Recent Fiscal Year)$9.56
Net Income$487.84 million
Net Margins24.20%
Return on Equity25.47%
Return on Assets13.30%
Miscellaneous
Employees1,260
Outstanding Shares60,410,000
Market Cap$9.42 billion
Jazz Pharmaceuticals (NASDAQ:JAZZ) Frequently Asked Questions
What is Jazz Pharmaceuticals' stock symbol?
Jazz Pharmaceuticals trades on the NASDAQ under the ticker symbol "JAZZ."
How were Jazz Pharmaceuticals' earnings last quarter?
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) issued its quarterly earnings data on Tuesday, August, 7th. The specialty pharmaceutical company reported $3.49 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $3.23 by $0.26. The specialty pharmaceutical company earned $500.48 million during the quarter, compared to the consensus estimate of $469.85 million. Jazz Pharmaceuticals had a return on equity of 25.47% and a net margin of 24.20%. View Jazz Pharmaceuticals' Earnings History.
When is Jazz Pharmaceuticals' next earnings date?
What guidance has Jazz Pharmaceuticals issued on next quarter's earnings?
Jazz Pharmaceuticals issued an update on its FY18 earnings guidance on Tuesday, August, 7th. The company provided earnings per share guidance of $12.75-13.25 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $13.04. The company issued revenue guidance of $1880-1930 million, compared to the consensus revenue estimate of $1.90 billion.
What price target have analysts set for JAZZ?
18 equities research analysts have issued twelve-month price objectives for Jazz Pharmaceuticals' shares. Their predictions range from $167.00 to $219.00. On average, they anticipate Jazz Pharmaceuticals' stock price to reach $192.8235 in the next year. This suggests a possible upside of 23.6% from the stock's current price. View Analyst Price Targets for Jazz Pharmaceuticals.
What is the consensus analysts' recommendation for Jazz Pharmaceuticals?
18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jazz Pharmaceuticals in the last year. There are currently 3 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Jazz Pharmaceuticals.
What are Wall Street analysts saying about Jazz Pharmaceuticals stock?
Here are some recent quotes from research analysts about Jazz Pharmaceuticals stock:
- 1. HC Wainwright analysts commented, "We highlighted after 1Q that management seemed to be taking a decidedly conservative approach to guidance this year, and this quarter we again see a healthy beat with little or no full-year raise. We still think guidance is a bit conservative (we’re near the high end on REV and EPS), but besides a small revenue drag from the sale of Prialt, unfortunately there was a key underperformer holding Jazz guidance back: Vyxeos. Jazz’s newest growth driver, from its most recent acquisition, only grew modestly QoQ, missed consensus for the second straight quarter, and Jazz lowered the product’s 2018 guidance 12% at the midpoint to $115-135M." (8/9/2018)
- 2. According to Zacks Investment Research, "After lower-than-expected sales in 2017, Jazz’ sleep disorder drug, Xyrem witnessed improved volume trends in Q1. Management seems confident that Xyrem will continue to generate volume growth in 2018 and beyond. Jazz’s lead pipeline candidate JZP-110 complements its existing sleep disorder portfolio. Meanwhile, its newest drug Vyxeos is enjoying improving demand trends. Jazz is also actively evaluating business development deals to enhance its product line and pipeline. Shares of the company have outperformed the industry so far this year. However, Jazz has been facing supply constraints for leukemia drug, Erwinaze, due to constrained manufacturing capacity. These supply challenges are expected to continue in 2018. Estimate movement has been mixed ahead of the company’s Q2 earnings release. Jazz has a mixed record of earnings surprises in recent quarters." (7/16/2018)
- 3. Mizuho analysts commented, "We reiterate our Neutral rating and $150 PT post-1Q:18 beat & improved guidance. We think investors may now be concerned about deal risk in the name." (5/9/2018)
- 4. Cantor Fitzgerald analysts commented, "JAZZ’s purchase of PRV makes strategic sense to us. This morning, the acquisition of a Priority Review Voucher (PRV) by JAZZ was disclosed. The company is paying $110 million in cash for a PRV owned by Spark Therapeutics (ONCE, Overweight rated covered by Elemer Piros). Particularly when applied to a speed-to-market situation, we believe the PRV could be useful for JAZZ." (4/30/2018)
Who are some of Jazz Pharmaceuticals' key competitors?
Some companies that are related to Jazz Pharmaceuticals include ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Alexion Pharmaceuticals (ALXN), Shiseido (SSDOY), Teva Pharmaceutical Industries (TEVA), BioMarin Pharmaceutical (BMRN), UCB (UCBJF), Mylan (MYL), Ono Pharmaceutical (OPHLF), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), Perrigo (PRGO), Sarepta Therapeutics (SRPT), Genmab A/S (GNMSF) and Bausch Health Companies (BHC).
Who are Jazz Pharmaceuticals' key executives?
Jazz Pharmaceuticals' management team includes the folowing people:
- Mr. Bruce C. Cozadd, Co-Founder, Exec. Chairman & CEO (Age 54)
- Mr. Matthew P. Young, Exec. VP & CFO (Age 49)
- Ms. Suzanne Sawochka Hooper, Exec. VP & Gen. Counsel (Age 52)
- Mr. Daniel N. Swisher Jr., Pres & COO (Age 55)
- Ms. Karen J. Wilson, Sr. VP of Fin. & Principal Accounting Officer (Age 55)
Who are Jazz Pharmaceuticals' major shareholders?
Jazz Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Strs Ohio (0.32%), Bank of Montreal Can (0.16%), PGGM Investments (0.08%), Andra AP fonden (0.06%), Tealwood Asset Management Inc. (0.06%) and Nisa Investment Advisors LLC (0.04%). Company insiders that own Jazz Pharmaceuticals stock include Bruce C Cozadd, Iain Mcgill, Karen J Wilson, Kenneth W O'keefe, Matthew P Young, Michael Patrick Miller, Patrick G Enright, Paul L Berns, Paul Treacy, Rick E Winningham, Russell J Cox and Suzanne Sawochka Hooper. View Institutional Ownership Trends for Jazz Pharmaceuticals.
Which institutional investors are selling Jazz Pharmaceuticals stock?
JAZZ stock was sold by a variety of institutional investors in the last quarter, including Strs Ohio, Tealwood Asset Management Inc., Xact Kapitalforvaltning AB and Atria Investments LLC. Company insiders that have sold Jazz Pharmaceuticals company stock in the last year include Bruce C Cozadd, Iain Mcgill, Karen J Wilson, Matthew P Young, Michael Patrick Miller, Patrick G Enright, Paul Treacy and Rick E Winningham. View Insider Buying and Selling for Jazz Pharmaceuticals.
Which institutional investors are buying Jazz Pharmaceuticals stock?
JAZZ stock was acquired by a variety of institutional investors in the last quarter, including Bank of Montreal Can, PGGM Investments, Nisa Investment Advisors LLC, We Are One Seven LLC, Oakbrook Investments LLC, Aperio Group LLC, State of Alaska Department of Revenue and Andra AP fonden. View Insider Buying and Selling for Jazz Pharmaceuticals.
How do I buy shares of Jazz Pharmaceuticals?
Shares of JAZZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Jazz Pharmaceuticals' stock price today?
One share of JAZZ stock can currently be purchased for approximately $155.99.
How big of a company is Jazz Pharmaceuticals?
Jazz Pharmaceuticals has a market capitalization of $9.42 billion and generates $1.62 billion in revenue each year. The specialty pharmaceutical company earns $487.84 million in net income (profit) each year or $9.56 on an earnings per share basis. Jazz Pharmaceuticals employs 1,260 workers across the globe.
What is Jazz Pharmaceuticals' official website?
How can I contact Jazz Pharmaceuticals?
Jazz Pharmaceuticals' mailing address is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. The specialty pharmaceutical company can be reached via phone at 353-1634-7800 or via email at [email protected]
MarketBeat Community Rating for Jazz Pharmaceuticals (NASDAQ JAZZ)
MarketBeat's community ratings are surveys of what our community members think about Jazz Pharmaceuticals and other stocks. Vote "Outperform" if you believe JAZZ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JAZZ will underperform the S&P 500 over the long term. You may vote once every thirty days.
